Study in JAMA Network Open Examines Impact of Hepatitis Drug Price Reductions on Manufacturer and Health Care Organization Revenue


July 5, 2019

JAMA Netw Open. 2019;2(7):e196541. doi:10.1001/jamanetworkopen.2019.6541

Pharmaceutical manufacturers rarely reduce drug list prices, but 3 expensive treatments for hepatitis C experienced significant list price reductions in 2018. Understanding the impetus for these price reductions could inform policies to reduce drug spending.

PLEASE READ THE FULL STUDY ON JAMANETWORK.COM